SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): December 6, 2006 (December 6,
2006)
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
1.02. Termination of a Material Definitive Agreement
On
December 6, 2006, Chembio Diagnostics, Inc. (the “Company”) announced that Avi
Pelossof, the Company’s Vice President of Sales, Marketing and Business
Development,
voluntarily resigned from his position
with the
Company effective January 31, 2007, to join Inverness Medical Innovations,
Inc.
Mr. Pelosoff has been employed with the Company under an employment contract
that was entered into in May 2004. Mr. Pelosoff's current salary is $170,000
per
annum.
ITEM
5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On
December 6, 2007, Avi Pelossof, Vice President of Sales, Marketing and Business
Development of the Company, announced he will voluntarily resign from his
position with the Company effective January 31, 2007. Mr. Pelossof’s resignation
from the Company was not the result of any disagreement with the Company.
ITEM
7.01. Regulation FD Disclosures.
On
December 6, 2006, the Company issued the press release titled “Chembio’s Avi
Pelossof Joining Inverness” included herein as Exhibit 99.1.
ITEM
9.01. Financial Statements and Exhibits
| (d) |
Exhibits.
|
| 99.1 |
Press
Release titled “Chembio’s Avi Pelossof Joining
Inverness” issued December 6, 2006.
|
In
accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K shall not be deemed “filed” for the purpose of
Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing. This Current Report on Form 8-K
does
not constitute a determination of whether any information included herein
is
material
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: December 6, 2006 Chembio
Diagnostics, Inc.
By: /s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer